ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 90 filers reported holding ALX ONCOLOGY HLDGS INC in Q4 2020. The put-call ratio across all filers is 0.71 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $244,587 | -35.3% | 50,957 | +1.2% | 0.00% | – |
| Q2 2023 | $378,128 | +214745.5% | 50,350 | +29.4% | 0.00% | – |
| Q1 2023 | $176 | -58.9% | 38,907 | +2.4% | 0.00% | -100.0% |
| Q4 2022 | $428 | -99.9% | 37,977 | +16.8% | 0.00% | – |
| Q3 2022 | $311,000 | +32.3% | 32,510 | +12.2% | 0.00% | – |
| Q2 2022 | $235,000 | -24.4% | 28,987 | +57.8% | 0.00% | – |
| Q1 2022 | $311,000 | -16.4% | 18,373 | +6.1% | 0.00% | – |
| Q4 2021 | $372,000 | -71.4% | 17,319 | -1.7% | 0.00% | -100.0% |
| Q3 2021 | $1,301,000 | +46.8% | 17,621 | +8.7% | 0.00% | +100.0% |
| Q2 2021 | $886,000 | -34.3% | 16,206 | -11.3% | 0.00% | -50.0% |
| Q1 2021 | $1,348,000 | +42.6% | 18,275 | +66.7% | 0.00% | +100.0% |
| Q4 2020 | $945,000 | +203.9% | 10,964 | +33.1% | 0.00% | – |
| Q3 2020 | $311,000 | – | 8,237 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |